Uniqure NV at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Hello, everyone. My name is Gena Wang, SMID cap biotech analyst at Barclays. It is my great pleasure to introduce our next presenting company, uniQure. With me on the screen is Matt Kapusta, Chief Executive Officer from uniQure. Matt, do you want to kick off with a brief introduction about -- overview about uniQure?
Yes. Sure. Well, first, Gena, thank you for having us here at the conference. We're delighted to see you over video. So I'm Matt Kapusta, Chief Executive Officer of uniQure. So at a high level, uniQure is one of the leading pioneers in the exciting field of genetic medicine. The company was founded in 1998 and was the sponsor of the first approved gene therapy in the western world, which is a product called Glybera. That was approved in Europe for the treatment of lipoprotein lipase deficiency in 2012.
And what I think this opportunity afforded us beyond the experience of bringing a highly innovative
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |